Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia von Park, I-K, Mundy-Bosse, B, Whitman, S P, Zhang, X, Warner, S L, Bearss, D J, Blum, W, Marcucci, G, Caligiuri, M A

Volltext

Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma von Sankar, S, Bell, R, Stephens, B, Zhuo, R, Sharma, S, Bearss, D J, Lessnick, S L

Volltext

The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients von Boysen, J, Sinha, S, Price-Troska, T, Warner, S L, Bearss, D J, Viswanatha, D, Shanafelt, T D, Kay, N E, Ghosh, A K

Volltext

A phase Ia/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumours von Sarantopoulos, J., Fotopoulos, G., Tsai, F Y -C, Beg, M.S., Adjei, A.A., Lou, Y., Seetharam, M., Villalona-Calero, M.A., Melear, J., Janat-Amsbury, M., Beever, H., Mouritsen, L., Wade, M., Bryan, B.V., Bearss, D.J.

Volltext

460P - A phase Ia/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumours von Sarantopoulos, J., Fotopoulos, G., Tsai, F Y -C, Beg, M.S., Adjei, A.A., Lou, Y., Seetharam, M., Villalona-Calero, M.A., Melear, J., Janat-Amsbury, M., Beever, H., Mouritsen, L., Wade, M., Bryan, B.V., Bearss, D.J.

Volltext

536MO A phase I, first-in-human, safety, pharmacokinetic, and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumours von Adjei, A.A., Beg, M., Melear, J., Thompson, J., Tsai, F.Y-C., Baranda, J.C., Bastos, B., Spira, A., Lou, Y., Seetharam, M., Uemura, M., Camidge, D.R., Yamamoto, N., Cowey, C.L., Doi, T., Anthony, S.P., Janat-Amsbury, M., Wade, M., Bearss, D.J., Sarantopoulos, J.

Volltext

639 Soluble Axl (sAxl) from serum defines a subpopulation of patients with breast, colon, lung, and pancreatic cancers von Warner, S.L, Wade, M.L, Call, L.T, Vankayalapati, H, Firpo, M.A, Mulvihill, S.J, Bearss, D.J, Sharma, S

Volltext

571 POSTER Modulation of JAK2 signaling pathways in vitro and in vivo by SGI-1252, a potent small molecule JAK2 inhibitor von Olsen, C.E, Gourley, E.S, Liu, X, Vankayalapati, H, Vollmer, D, Severson, P, Bearss, J, Jones, C, Bearss, D.J, Warner, S.L

Volltext

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-[x.sub.L] dependence with alvocidib response von Pierceall, W.E, Warner, S.L, Lena, R.J, Doykan, C, Blake, N, Elashoff, M, Hoff, D.V, Bearss, D.J, Cardone, M.H, Andritsos, L, Byrd, J.C, Lanasa, M.C, Grever, M.R, Johnson, A.J

Volltext

126 Development of a new series of tricyclic pyrimido-indole inhibitors targeting Aurora kinases von Warner, S.L., Vankayalapati, H., Bashyam, S., Grand, C.L., Han, H., Von Hoff, D.D., Hurley, L.H., Bearss, D.J.

Volltext